Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Aug 06, 2023 1:49pm
410 Views
Post# 35575472

Upcoming well needed updates …

Upcoming well needed updates …

This Thursday is the " fireside chat", then the following Monday the Q2 results.
i expect an update ASAP on the recent bought deal financing being closed etc.
An " update/ explanation " of that $$ deal would certainly be welcome.
The N.R. Said to assist in phase 3 trials. Being MBc & pancreatic cancer.
That is too vague imho
For those counting, there are about 40-45 days left of the PanCan invite " further details within 90 days"
CAR-T " deal" long over due. 

I understand they will be presenting at some cancer conference in October?
lots of questions needing answers.
The fireside chat in of itself won't have any ground breaking news. That would need to come in a formal N.R.
Looking at company presentation, they are within a few months of a lot of things.
We all want a business development deal. Everyone knows that.
The pharmas want to see data, 
so.....we wait.


 

<< Previous
Bullboard Posts
Next >>